Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer.

Trial Profile

Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 May 2017

At a glance

  • Drugs Dutasteride (Primary) ; Bicalutamide; Goserelin; Ketoconazole; LHRH receptor agonists; Prednisone
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 26 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 09 Dec 2013 Results published in the Journal of Clinical Oncology.
    • 09 Jan 2012 Planned end date changed from 1 Oct 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top